¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"factor ix assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤, ¸²ÇÁ±¸¼¼Æ÷µ¶¼º°Ë»ç
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤(¹ý), ÇöóÅ©ÃøÁ¤(¹ý)
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • radial partition immunofluorometric assay
    ¹æ»çºÐÇҸ鿪Çü±¤ÃøÁ¤
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    Ãʰú»êÈ­¹°ÃøÁ¤
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÎÀÚ, Ç׎½ÄÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • antirachitic factor
    Ç×±¸·çº´ÀÎÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤¹ý, ÇöóÅ©ÃøÁ¤¹ý
  • radial partition immunofluorometric assay
    ¹æ»ç¼ººÐÇҸ鿪Çü±¤ÃøÁ¤
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    °ú»êÈ­¹°ÃøÁ¤
  • dilution assay technique
    Èñ¼®ºÐ¼®¹ý
  • hemizona assay index
    ¹ÝÅõ¸í¶ìÃøÁ¤ÁöÇ¥
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • antihemophlic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibiotic assay
    Ç×»ý¹°Áú ¹ÙÀÌ¿ÀÆò°¡.
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigenic assay
    Ç׿ø¼ººÐ¼®
  • antimicobial assay
    Ç×±ÕÁ¦ÃøÁ¤
  • growth hormone assay
    ¼ºÀåÈ£¸£¸óÃøÁ¤
  • hemizona assay (index)
    ¹ÝÅõ¸í´ë ÃøÁ¤(ÁöÇ¥)
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • immunoconcentration assay
    ¸é¿ª³óÃàÃøÁ¤<--Á¤·®
  • immunoenzymometric assay
    ¸é¿ªÈ¿¼Ò°èÃø<--°è·®>ºÐ¼®
  • immunofluorescence assay
    ¸é¿ªÇü±¤°Ë»ç
  • immunometric assay
    ¸é¿ª°è·®<--°èÃø>°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • plaque assay
    ÇöóÅ© ÃøÁ¤¹ý
  • plaque assay, hemolytic
    ¿ëÇ÷¼º ÇöóÅ© Çü¼º½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bacterial killing assay
    ¼¼±Õ»ìÇØÃøÁ¤
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • biological assay
    Àθí[¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ] »ý¹°ÇÐÀû ¾Æ¼¼ÀÌ(¡­ËþïÒ).
  • biological assay
    »ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ)
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • calcitonin assay
    Ä®½ÃÅä´ÑÃøÁ¤
  • carcinoembryonic antigen assay
    ¾Ï(¼º)¹è¾Æ¼º Ç׿øÃøÁ¤
  • cell adhesive matrix assay
    ¼¼Æ÷Á¡Âø±âÁúºÐ¼®
  • clonogenic assay
    Ŭ·Ð¿ø¼º ºÐ¼®
  • clonogenic assay
    Ŭ·Ð¿ø¼ººÐ¼®
  • colony formation assay
    Áý¶ôÇü¼º´ÉÃøÁ¤
  • creatine kinase assay
    Å©·¹¾ÆÆ¾Å°³ªÁ¦ÃøÁ¤
  • diagnostic assay
    Áø´ÜÀûºÐ¼®
  • dilution assay technique
    Èñ¼®ºÐ¼®¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunofluorometric assay
    ¸é¿ªÇü±¤ÃøÁ¤(Øóæ¹û«ÎÃö´ïÒ) ¾Æ½êÀÌ
  • immunoradiometric assay
    ¸é¿ª¹æ»ç´ÉÃøÁ¤(Øóæ¹Û¯ÞÒÒöö´ïÒ) ¾Æ½êÀÌ
  • in situ hybridization assay
    Á¦ÀÚ¸® Æ¢±â»ý¼º(ßæà÷) ¾Æ½êÀÌ
  • kinetic assay
    ¿ªµ¿(æ³ÔÑ)¾Æ½êÀÌ
  • linked assay
    ¿¬°è(ææÍ¨)¾Æ¼¼ÀÌ
  • linked enzyme assay procedure
    ¿¬°èÈ¿¼Ò(ææÍ¨ý£áÈ) ¾Æ½êÀÌ ¹æ½Ä(Û°ãÒ)
  • microbiological assay
    ¹Ì»ý¹°(Ú°ßæÚª)¾Æ¼¼ÀÌ
  • plaque assay
    ÇöóÅ© ¾Æ½êÀÌ
  • radioisotopic enzyme assay
    ¹æ»ç¼º µ¿À§¿ø¼Ò È¿¼Ò(Û¯ÞÒàõÔÒêÈêªáÈý£áÈ) ¾Æ½êÀÌ
  • rat antidiuresis assay
    Áã Ç×ÀÌ´¢(ù÷××Òã) ¾Æ½êÀÌ
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • achromotrichia factor
    ¸ð¹ß»ö¼Ò°áÇÌÀÎÀÚ (Ù¾Û¥ßäáÈÌÀù¹ì×í­)
  • angiogenic factor
    Ç÷°üÇü¼ºÀÎÀÚ(úìηû¡à÷ì×í­)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anti-egg-white injury factor
    Ç׳­¹é ¼Õ»óÀÎÀÚ(ù÷ÑëÛÜáßß¿ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
LAI assay Leukocyte Adherence Inhibition assay
ERA electrical response activity; electroencephalic response audiometry; Electroshock Research Associati...
IFA idiopathic fibrosing alveolitis; immunofluorescence assay; immunofluorescent antibody; incomplete Fr...
DF decapacitation factor; decontamination factor; deferoxamine; deficiency factor; defined flora [anima...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DFA Direct immunofluorescence assay
Dot-ELISA Dot Enzyme-Linked Immunosorbent Assay
DIA Dot immunobinding assay
EIA Electro Immuno-Assay
EMSA Electrophoresis mobility shift assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • human zona binding assay
    »ç¶÷ Á¤ÀÚ Åõ¸í´ë ºÎÂø °Ë»ç
  • microbiological assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • micrologica assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • radioreceptor assay
    ¹æ»ç¼± ¼ö¿ëü ÃøÁ¤¹ý
    ÀÏÁ¾ÀÇ ¹æ»ç Ç¥Áö °ËÁ¤¹ýÀ¸·Î¼­, Á¶Á÷ Ç¥º» ³»¿¡ Àִ ȣ¸£¸ó¿¡ ´ëÇØ Ư¼öÇÑ ¼¼Æ÷ ¼ö¿ëüÀÇ ³óµµ¸¦ ¹æ»ç Ç¥ÁöÇÑ È£¸£¸óÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÏ´Â °Í.
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • accessory food factor
    ¿µ¾ç º¸Á¶ ÀÎÀÚ
    F.G Ho
  • air kerma calibration factor
    °ø±â Ä¿¸¶ ÃøÁ¤ °è¼ö, ´«±Ý ¸ÂÃã °è¼ö
  • alveolar dilution factor
    ÆóÆ÷ Èñ¼® ÀÎÀÚ
  • angiogenesis factor
    Ç÷°ü Çü¼º ÀÎÀÚ
    ½Å»ý Ç÷°ü Áõ½ÄÀ» À¯µµÇÏ´Â ¹°Áú·Î¼­, Á¾¾çÀ̳ª ¸Á¸· °°Àº ½ÅÁø´ë»ç·®ÀÌ Å« Á¶Á÷¿¡¼­ ¹ß°ßµÈ´Ù. ÀÌ ÀÎÀÚ´Â »óóÀÇ °¡ÀåÀÚ¸®³ª Ç¥¸é¿¡ ÀÖ´Â Àú»ê¼Ò »óÅÂÀÇ ´ë½Ä¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç, »óó Ä¡À¯ °úÁ¤¿¡¼­ Ç÷°ü ÀçÇü¼ºÀ» À¯µµÇÑ´Ù.
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
  • antihemophilic factor
    Ç×Ç÷¿ìº´ ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰 ÀÎÀÚ
  • antistiffness factor
    Ç×°­Á÷ ÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ¼º ³ªÆ®·ý ÀÌ´¢ ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
radioligand assay <radiobiology> Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labelled binding reagents (e.g., antibodies, intracellular receptors, plasma binders).
(12 Dec 1998)
radioreceptor assay A competitive binding assay in which the binder is a membrane or tissue receptor rather than an antibody.
(05 Mar 2000)
Raji cell radioimmune assay For immune complexes; a procedure by which immune complexes adsorbed from a test serum by a standard preparation of lymphoblastoid (Raji) cells are assayed by the capacity to bind 125I-labelled antibody to immunoglobulin.
(05 Mar 2000)
gel retardation assay A lab technique used to find out if there are proteins binding a fragment of DNA (in a DNA-protein complex) by watching how fast the DNA fragment moves through an electric field and seeing whether it moves slower when a particular protein is also present.
(09 Oct 1997)
checkerboard assay <procedure> Variant of the Boyden chamber assay for leucocyte chemotaxis introduced by Zigmond. By testing different concentrations of putative chemotactic factor in nongradient conditions, it is possible to calculate the enhancement of movement expected due simply to chemokinesis and to compare this with the distances moved in positive and negative gradients. Good experimental design thus allows chemotaxis to be distinguished from chemokinesis.
(21 May 1997)
chloramphenicol acetyltransferase assay <investigation> A lab technique used to determine whether a given fragment of DNA has a promoter on it to encourage transcription to occur, by attaching the gene (called the CAT gene) which codes for the CAT enzyme to it, and observing whether the CAT enzyme is produced.
(05 Jan 1998)
Grunstein-Hogness assay A procedure for identifying plasmid clones by colony hybridization.
(05 Mar 2000)
clonogenic assay In vitro culturing of neoplastic cells to test their radiosensitivity or chemosensitivity, and probable clinical efficacy of a therapeutic agent.
(05 Mar 2000)
colony-forming units assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
(12 Dec 1998)
competitive binding assay General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards.
See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym: displacement analysis, saturation analysis.
(05 Mar 2000)
complement binding assay A test for the detection of immune complexes.
(05 Mar 2000)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
plaque assay 1. <investigation> Assay for virus in which a dilute solution of the virus is applied to a culture dish containing a layer of the host cells, convective spread is prevented by making the medium very viscous. After incubation the plaques, areas in which cells have been killed (or transformed), can be recognised and the number of infective virus particles in the original suspension estimated.
2. Assay for cells producing antibody against erythrocytes or against antigen that has been bound to the erythrocytes. The cell is surrounded by a clear plaque of haemolysis. Basic principle behind the assay is the same as for the virus plaque assay.
(18 Nov 1997)
haemolytic plaque assay <investigation> A haemolytic plaque assay is a lab technique used to show that certain antibodies are secreted by antibody-making cells when these cells are mixed with red blood cells.
The mixture is spread onto a plate of agar, if a plaque appears, it means that the red blood cells have been destroyed (by haemolysis) by the antibodies.
(09 Oct 1997)
progesterone receptor assay The progesterone receptor test (PgR assay) checks the tumour for its hormone status.
(16 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á